myprivateMD

Survivor Hope

Atherosclerotic Plaque Stabilization and Regression in Elderly Cardiac Event Survivors

1. Introduction and Context

Margaret, a 72-year-old retired schoolteacher, exercised three mornings a week, cooked dinner for her grandchildren every Sunday, and managed her blood pressure with a single medication. Then, on an ordinary Tuesday afternoon, she experienced sudden weakness in her right arm and difficulty finding words. Within hours, she was diagnosed with an ischemic stroke caused by atherosclerotic disease in her carotid arteries. Her neurological deficits resolved, but a conviction set in: her body had betrayed her, the damage was permanent, and she was simply waiting for the next event.

Margaret's response is the norm. Post-stroke depression affects 27% of survivors overall, with 30% prevalence within the first month and 22% persisting at six to twelve months[1]. Fear, fatalism, and the belief that "the damage is done" are among the most common and dangerous psychological responses to cardiovascular events, undermining the adherence behaviors that determine whether a survivor lives or dies[2]. Poststroke cognitive impairment—affecting 17 to 60% of survivors—further compounds the challenge by limiting the ability to engage with complex medical instructions[3].

The stakes are substantial. Stroke affects 7.7% of Americans aged 65 and older[4] [5]. Combined with myocardial infarction survivors, an estimated 12 to 15% of elderly Americans—roughly 5 to 6 million individuals—are cardiovascular event survivors at high risk for recurrence[4-1]. Among these survivors, three-year all-cause mortality reaches 34%, with 8% experiencing recurrent stroke within three years[6], and 7.2% of MI survivors experiencing recurrent infarction within the first year[7].

But something fundamental has changed in cardiovascular medicine. For decades, medical consensus held that atherosclerosis was irreversible. Plaque accumulated. Arteries narrowed. The best physicians could offer was slowing progression. This fatalistic paradigm dominated medical thinking through the early 2000s[8].

The paradigm began shifting in the 1990s, when CLAS and MARS provided the first serial imaging evidence that established lesions could be reversed with lipid-lowering therapy[9]. The turning point came between 2001 and 2006, when the REVERSAL trial demonstrated that high-intensity atorvastatin halted progression more effectively than moderate-intensity pravastatin[8-1], and ASTEROID proved that very intensive rosuvastatin therapy achieved measurable plaque regression[10]. By 2016, GLAGOV showed that adding PCSK9 inhibitors to statins produced even greater regression. The message was no longer "slow the damage." The message became "reverse it."

What Makes a Study "Level A" Evidence? (Click to Expand)

Medical evidence is graded on a hierarchy reflecting the strength of the study design. Understanding this hierarchy helps readers evaluate the claims throughout this paper.

Level A (Strongest): Systematic reviews and meta-analyses of multiple randomized controlled trials. These pool data from thousands of patients across multiple studies, reducing the risk that a single study's quirks drive the conclusion. Examples in this paper: the Iatan 2023 meta-regression of 7,407 patients, the Cochrane review of home-based cardiac rehabilitation.

Level B□R (Randomized): Individual randomized controlled trials. Patients are randomly assigned to treatment or placebo, minimizing bias. Examples: GLAGOV, the Lyon Diet Heart Study, and PACMAN-AMI.

Level B□NR (Non-Randomized): Well-designed observational studies, registries, and cohort analyses. These identify associations but cannot prove causation with the same rigor as RCTs. Examples: ASTEROID (open-label, single-arm), Canadian ACS Registries (Yan et al.), Singapore Myocardial Infarction Registry.

Level C (Consensus): Expert opinion and consensus statements based on clinical experience when trial data are unavailable. Example: optimal monitoring intervals, exercise progression guidelines in very elderly.

Throughout this paper, the evidence level supporting each recommendation is noted. Where only observational or consensus-level evidence exists, that limitation is explicitly acknowledged.

This white paper serves as a companion to Video 03 in the Prevention Video Series: "To The Survivor: It's Not Too Late." It expands on the clinical evidence, provides mechanistic depth a five-minute video cannot accommodate, and equips survivors, caregivers, and healthcare providers with the knowledge needed to act. The central message: **your arteries can heal. It is not too late.**

2. Mechanism and Pathophysiology

What You Need to Know

The event that brought you to this paper was caused by atherosclerosis. But atherosclerosis is not a permanent sentence. When treated aggressively, the dangerous plaques in your arteries can stabilize, shrink, and become dramatically less likely to cause another event. This section explains how that healing happens at the biological level.

How Atherosclerosis Develops

Atherosclerosis begins with damage to the endothelium, the single-cell layer lining every artery. Hypertension, diabetes, smoking, and metabolic dysfunction injure this barrier, allowing cholesterol-carrying particles (particularly LDL) to penetrate the artery wall[10-1]. Once inside, these particles become oxidized and trigger an immune response. White blood cells called monocytes cross the endothelium and differentiate into macrophages, which engulf the oxidized cholesterol, swelling into "foam cells." Your immune system's cleanup crew rushes in, but instead of fixing the problem, they gorge on cholesterol and become part of it. These foam cells release inflammatory molecules that amplify the inflammatory cascade, recruiting more immune cells and perpetuating the cycle[11].

Over years, this process creates a plaque: a lipid-rich necrotic core covered by a fibrous cap made of smooth muscle cells and collagen. Think of it as a water balloon embedded in your artery wall. When the wall is thick and strong, the plaque is stable. When it thins and weakens under inflammatory assault, the plaque becomes vulnerable to rupture. The inflammatory process degrades the cap through destructive enzymes that dissolve the collagen holding the cap together while preventing smooth muscle cells from repairing the damage[12].

Plaque rupture causes heart attacks and most strokes. The average fibrous cap thickness in vulnerable plaques measures roughly 56 micrometers— less than the width of a human hair[12-1]. When this cap tears, the lipid core is exposed to flowing blood, triggering sudden clot formation that blocks the artery. Approximately 60 to 70% of heart attacks result from plaque rupture rather than gradual narrowing[10-2].

The Four Pathways of Plaque Healing



Figure 1: Four Pathways of Plaque Healing. Comprehensive visualization showing how intensive therapy reverses atherosclerosis through fibrous cap thickening, lipid core reduction, inflammation control, and endothelial recovery.

Healing operates through four distinct but synergistic pathways, all activated by the treatments described in Section 4.

Pathway 1 Fibrous Cap Thickening. Aggressive lipid-lowering therapy stimulates smooth muscle cell proliferation and collagen synthesis within the cap, physically strengthening the plaque. The PACMAN-AMI trial demonstrated that adding alirocumab (a PCSK9 inhibitor) to high-intensity statin therapy nearly doubled the cap thickening achieved by statin alone—62.67 versus 33.19 micrometers of new cap growth at 12 months[12-2]. Your artery walls are getting stronger, and combination therapy makes them stronger faster.

Pathway 2 Lipid Core Reduction. Treatment reduces the lipid core volume by decreasing new LDL deposition and increasing cholesterol efflux— the process by which cholesterol is actively removed from the plaque and returned to the liver for disposal. The ASTEROID trial demonstrated a median 6.8% reduction in total atheroma volume with intensive rosuvastatin therapy over 24 months[10-3]. The GLAGOV trial showed that adding evolocumab to statins achieved 2.9% plaque volume regression compared to 0.4% with statin alone[13]. The dangerous buildup is shrinking.

Pathway 3 Inflammation Reduction. Statins and other therapies reduce the inflammatory activity that drives plaque instability. The REVERSAL trial documented a 36.4% reduction in C-reactive protein with high-intensity atorvastatin[11-1]. The PROVE IT-TIMI 22 trial demonstrated that patients achieving both LDL below 70 mg/dL and CRP below 2 mg/L had 28 to 33% lower major adverse cardiovascular event rates[11-2] [14]. Your arteries are calming down.

Pathway 4 Endothelial Function Recovery. Treatment improves the arterial lining, increasing production of nitric oxide—a natural chemical that relaxes and opens blood vessels—and improving the artery's ability to dilate[15]. Physicians can measure this improvement using a test called flowmediated dilation, which shows gains within weeks of statin initiation. Exercise compounds this effect: the physical force of blood flowing through your arteries during activity triggers additional nitric oxide release, further relaxing and protecting vessel walls[15-1]. This reduces clotting risk and creates a healthier vascular environment. Your blood vessels are working better.

The Synergy Principle: Why Four Pathways Matter More Than One (Click to Expand)

These four pathways do not operate in isolation. They are synergistic, meaning the combined effect exceeds the sum of individual contributions. Fibrous cap thickening stabilizes existing plaques. Lipid core reduction shrinks the "fuel" for future rupture. Inflammation reduction slows cap degradation while allowing repair. Endothelial recovery restores the artery's first line of defense against new plaque formation.

This is why combination therapy (statin plus lifestyle plus cardiac rehabilitation, and sometimes PCSK9 inhibitors or ezetimibe) produces dramatically better outcomes than any single intervention alone. The GLAGOV trial's 2.9% plaque regression with combination therapy versus 0.4% with statin alone illustrates this principle at the plaque level[13-1]. The Yan et al. data showing 46% mortality reduction with full OMT versus partial therapy illustrates it at the clinical outcomes level[16].

This is biological engineering, not wishful thinking.

From Mechanism to Measurable Outcomes

Figure 2: Three Types of Proof. Laboratory markers drop within weeks. Functional capacity improves within months. Clinical outcomes prove treatment works over years.

You will see proof that healing is happening through three kinds of evidence.

Laboratory proof. LDL cholesterol drops within 4 to 6 weeks on statins and reaches steady state by 12 weeks on PCSK9 inhibitors[17]. CRP reduction is measurable by 8 to 12 weeks. Every quarterly lab check showing downward trends reflects real biological change in your arterial walls.

Functional proof. Cardiac rehabilitation produces a mean 21.8% improvement in 6-minute walk test performance, from 432 to 527 meters[18]. Walking further without fatigue and resuming activities you had stopped correlate directly with measurable improvements in cardiovascular capacity[18-1].

Clinical proof. Every year without a recurrent event is proof that treatment is working. Statin therapy initiated after first stroke reduces 10-year recurrence rates from 16.3% to 7.5%, demonstrating that benefits persist without fading[19].

Healing Timeline

Phase	Timeframe	What Is Happening
Early changes	Weeks 1-12	LDL falls, CRP drops, endothelial function improves
Intermediate changes	3-6 months	Lipid core begins shrinking, cap thickening starts, inflammation sustains lower levels
Established changes	12-24 months	Fibrous cap thickening near maximal, plaque volume regression measurable, vulnerable features reduced
Long-term maintenance	Years 2-10+	Benefits accumulate and persist; each year at target adds to total benefit

3. Evidence Base

For the interventions discussed in this paper, the evidence ranges from robust (Level A, systematic reviews and large registries) to strong (Level B-R, individual randomized controlled trials).

Landmark Imaging Trials

Three imaging studies form the foundation of plaque regression evidence.

The **ASTEROID trial** (2006) enrolled 507 patients with stable coronary artery disease and treated them with rosuvastatin 40 mg daily for 24 months. LDL cholesterol fell from 130.4 to 60.8 mg/dL. The primary finding was a median 6.8% reduction in total atheroma volume and 0.98% regression in percent atheroma volume—meaning the proportion of the artery wall occupied by plaque measurably shrank—as measured by intravascular ultrasound[10-4]. Regression was observed in 63.6% of patients.

The **GLAGOV trial** (2016) enrolled 968 patients and randomized them to evolocumab (a PCSK9 inhibitor) plus statin versus placebo plus statin for 76 weeks. The evolocumab group achieved LDL cholesterol of 36.6 mg/dL—well below the recommended target of 70—and demonstrated 2.9% plaque volume reduction compared to 0.4% in the placebo group[13-2]. More than 60% of patients on evolocumab experienced plaque

regression, with benefits extending to LDL levels as low as 20 mg/dL[13-3]. The subsequent FOURIER trial (27,564 patients) confirmed that evolocumab reduced major cardiovascular events by 15 to 20%[20], and ODYSSEY OUTCOMES demonstrated similar benefits for alirocumab[21].

The **Iatan 2023 meta-regression analysis** synthesized 23 prospective studies involving 7,407 patients and found that every 1% reduction in coronary plaque volume was associated with a 19 to 25% reduction in major adverse cardiovascular events[22]. Regression is not cosmetic. It saves lives.

Clinical Outcomes Trials

The 46% Mortality Reduction. The Canadian ACS I and ACS II Registries (Yan et al. 2007) studied 6,853 patients admitted for acute coronary syndromes and found that optimal medical therapy (aspirin, a second anti-clotting medication called a P2Y12 inhibitor, statin, beta-blocker, and ACE inhibitor/ARB) was associated with a 46% reduction in all-cause mortality at one year[16-1]. Despite this dramatic benefit, only 51.8% of eligible patients received optimal therapy at discharge, a treatment gap that persists today[16-2] [23].

The 61% Stroke Reduction. A 2024 multicenter prospective cohort study found that adding PCSK9 inhibitors to standard lipid-lowering therapy reduced early recurrent stroke from 5.59% to 2.16% in patients with symptomatic intracranial atherosclerotic stenosis—a 61% relative reduction[24]. The number needed to treat—that is, the number of patients who must receive this therapy for one additional patient to avoid a stroke—was approximately 29[24-1].

Number Needed to Treat. Statins in secondary prevention have a number needed to treat (NNT) of 30 to 37 over five years to prevent one death[25]. The 4S and LIPID trials achieved NNTs as low as 15 to 32 for preventing cardiovascular events[25-1]. For context: the NNT for aspirin in secondary prevention is approximately 50, and for beta-blockers post-MI approximately 42[25-2].

Understanding Number Needed to Treat (Click to Expand)

NNT tells you how many patients must receive a treatment for one additional patient to benefit. Lower numbers mean more effective treatment.

NNT Comparison Across Interventions:

- Cardiac rehabilitation (36 sessions): NNT ≈10-15 (estimated; registry data, likely partly reflects patient selection)
- Statins in secondary prevention: NNT 30-37 (5-year mortality)
- Beta-blockers post-MI: NNT ≈42 (mortality)
- Aspirin in secondary prevention: NNT ≈50 (mortality)
- Antihypertensives in primary prevention: NNT 100-200 (mortality)

Why NNT is BETTER in elderly patients: The same relative risk reduction (say 46%) produces a larger absolute benefit when baseline risk is higher. A 75-year-old with 5% annual event risk gets 2.3% absolute reduction (NNT 43), while a 40-year-old with 1% risk gets only 0.46% absolute reduction (NNT 220). Your age makes treatment MORE effective, not less.

Long-Term Persistence. Statin therapy initiated after first stroke reduces 10-year recurrence rates from 16.3% to 7.5%[19-1]. A meta-analysis of 11 randomized controlled trials involving 11,749 participants confirmed that statins reduced odds of stroke recurrence without increasing hemorrhagic stroke risk[19-2]. Benefits are sustained or even increase with longer treatment duration.

Age-Specific Evidence

Ages 75□85. Current guidelines recommend at least moderate-intensity statin therapy for all patients over age 75 with established cardiovascular disease[26]. Beta-blockers post-MI in patients aged 65 to 75 produce a 6% absolute mortality reduction[26-1]. Anticoagulation in patients aged 75 and older with atrial fibrillation reduces stroke risk by 52 to 64%[27].

Nonagenarians (90□□. The Singapore Myocardial Infarction Registry (2007-2020) studied patients aged 90 years and older following their first heart attack and found that a greater number of guideline-directed medical therapy classes was associated with longer survival at 1, 3, and 5 years[28]. Patients receiving all four recommended GDMT classes had the greatest survival benefit[28-1].

Why Elderly Benefit More, Not Less. Higher baseline risk translates to larger absolute risk reduction for the same relative benefit. An intervention producing 46% relative mortality reduction in a 40-year-old with 1% annual risk saves 0.46 lives per 100 patients treated. The same 46% reduction in a 75-year-old with 5% annual risk saves 2.3 lives per 100 patients[26-2].



Figure 3: Age Benefit Comparison. The same 46% relative mortality reduction produces 5 times greater absolute benefit in a 75-year-old (NNT 43) than a 40-year-old (NNT 220) because of higher baseline risk. Your age is a reason to treat aggressively, not to withhold therapy.

Evidence Summary Table

Key: TAV = Total Atheroma Volume | PAV = Percent Atheroma Volume | MACE = Major Adverse Cardiovascular Events | OMT = Optimal Medical Therapy | GDMT = Guideline-Directed Medical Therapy | CV = Cardiovascular | MI = Myocardial Infarction | CR = Cardiac Rehabilitation | PCSK9i = PCSK9 Inhibitor

Trial / Study	Design	Participants	Key Finding	Evidence Level
ASTEROID	Open-label, single-arm	507	6.8% TAV regression with rosuvastatin 40 mg	Level B-NR
GLAGOV	Randomized controlled trial	968	PCSK9i + statin: 2.9% regression vs 0.4% statin alone	Level B-R
Iatan 2023 Meta-regression	Systematic review, metaregression	7,407	Every 1% plaque regression = 19-25% MACE reduction	Level A
Yan et al. 2007 (Canadian ACS	Prospective registry	6,853	OMT: 46% all-cause mortality reduction at 1 year	Level B-NR
PCSK9i Stroke (Zhang 2024	Prospective cohort	Multi-center	61% reduction in early recurrent stroke	Level B-NR
Nonagenarian GDMT (Ong 2025	National registry	90+ years	Every GDMT class = longer survival at 1, 3, 5 years	Level B-NR
Lyon Diet Heart Study	Randomized controlled trial	605	Mediterranean diet: 70% reduction in CV deaths/MI	Level B-R
Cochrane HBCR (2023	Meta-analysis	Multiple RCTs	Home-based CR equally effective as center-based	Level A
PACMAN AMI (Fibrous Cap)	Randomized controlled trial	Post-MI	62.67 um cap thickening with alirocumab at 12 months	Level B-R
SELECT (GLP 1 RA	Randomized, double-blind	17,604	Semaglutide: 20% MACE reduction in overweight/obese CV patients	Level B-R
COLCOT / LoDoCo2 (Colchicine)	Randomized controlled trials	4,745 / 5,522	Low-dose colchicine: 23-31% MACE reduction in coronary disease	Level B-R
SAMSON (Nocebo	Crossover, double-blind	60	90% of statin "side effects" were nocebo	Level B-R

Evidence Limitations

Major plaque regression imaging trials (ASTEROID, GLAGOV) enrolled patients with mean ages of 58 to 60 years. No imaging trial has specifically enrolled or subanalyzed patients over age 75[29]. Fifty percent of cardiovascular trials have failed to enroll any participant over age 75[29-1].

However, the biological mechanisms of plaque regression are age-independent processes. Clinical outcomes trials demonstrate that lipid-lowering therapy benefits extend to age 90 and beyond, strongly suggesting that the plaque-level changes observed in younger patients occur in elderly populations as well[28-2].

4. Clinical Application

Optimal Medical Therapy: The Five Pillars

Optimal medical therapy (OMT) consists of five components proven to reduce mortality and recurrent events in cardiovascular survivors.

Pillar 1 Antiplatelet Therapy. Aspirin 81 mg daily prevents clot formation at sites of plaque disruption[16-3]. For 6 to 12 months after an acute coronary syndrome, a second antiplatelet agent is added as dual antiplatelet therapy. Post-stroke adherence to antiplatelets is the highest of any medication class at 97%[30]. The important exception: cardioembolic stroke from atrial fibrillation requires anticoagulation, not antiplatelets. Anticoagulation in patients aged 75 and older with atrial fibrillation reduces stroke risk by 52 to 64%[27-1].

Pillar 2 High-Intensity Statin Therapy. Atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily. The target is LDL cholesterol below 70 mg/dL, ideally below 55 mg/dL for very high-risk patients[26-3]. The Treat Stroke to Target trial confirmed that targeting LDL below 70 mg/dL after ischemic stroke produced superior outcomes[31]. Statins reduce LDL by 40 to 50%, reach peak effect within 4 to 6 weeks, and simultaneously reduce inflammation and stabilize plaques[17-1] [11-3].

Pillar 3 Beta-Blocker (Post-MI. Metoprolol, carvedilol, or bisoprolol reduce heart rate and cardiac workload[16-4]. Duration is at least three years post-MI, often indefinitely if heart failure or arrhythmia is present. Beta-blockers in patients aged 65 to 75 produce a 6% absolute mortality reduction[26-4] [25-3].

Pillar 4 ACE Inhibitor or ARB. These medications lower blood pressure and prevent adverse heart remodeling while providing vascular protection. The blood pressure target is below 130/80 mmHg, with gentler targets in the very elderly to reduce fall risk.

Pillar 5 Advanced Lipid-Lowering (When Needed). When statin therapy alone does not achieve LDL targets, ezetimibe adds an additional 15 to 20% LDL reduction[32]. Combination therapy with moderate-intensity statin plus ezetimibe achieves LDL below 70 mg/dL in over 80% of patients[32-1]. For the 15 to 30% who still do not reach goal, PCSK9 inhibitors (evolocumab, alirocumab, or inclisiran) provide 50 to 65% additional LDL reduction[20-1]. Inclisiran requires only twice-yearly injections with a mean LDL reduction of

50.2%, making it ideal for elderly patients concerned about medication burden[17-2] [33]. PCSK9 inhibitor pricing has fallen substantially since early adoption; 2017 data cited costs of $572 to $711 per month[34], but manufacturer list price reductions (approximately 60% for evolocumab in 2023) and the introduction of inclisiran— administered as a twice-yearly injection in the physician's office—have changed the cost landscape. Patients should verify current pricing with their pharmacy or insurance plan, as out-of-pocket costs now vary widely by agent and coverage pathway.

Beyond the Five Pillars: Emerging Targets

Lipoprotein(a). Lp(a) is an independent genetic risk factor for cardiovascular disease that does not respond to statins, diet, or exercise[35]. Unlike LDL cholesterol, Lp(a) levels are largely determined by your genes. Elevated Lp(a) increases the risk of heart attack and stroke beyond what standard risk factors predict. Ask your cardiologist whether Lp(a) testing is appropriate for you—targeted therapies are in late-stage clinical trials and may soon expand treatment options for patients with elevated levels.

Anti-Inflammatory Therapy. The five pillars address cholesterol, clotting, blood pressure, and heart remodeling. An emerging target is residual inflammatory risk—the inflammation that persists even after LDL and blood pressure reach goal. Two landmark trials—COLCOT and LoDoCo2— demonstrated that low-dose colchicine, a well-established anti-inflammatory medication, reduced major cardiovascular events by 23 to 31% when added to standard therapy in patients with coronary artery disease[36] [37]. This approach is explored in detail in Video 05 of this series. Discuss with your cardiologist whether anti-inflammatory therapy may be appropriate for your situation.



Figure 4: The Five Pillars of Optimal Medical Therapy. Architectural visualization showing the five evidence-based medication components (Antiplatelet, High-Intensity Statin, Beta-Blocker, ACE-I/ARB, Advanced Lipid-Lowering) that together achieve 46% mortality reduction in cardiovascular survivors. Only 48–52% of elderly survivors receive all five components.

Understanding the Treatment Gap (Click to Expand)

Despite the 46% mortality reduction associated with OMT, only 48 to 52% of elderly survivors receive all recommended components[23-1] [16-5].

Prescription rates decline over time: statin use drops from 60.5% at three years to 55.2% at six years post-stroke[23-2]. Women and elderly patients are paradoxically less likely to receive evidence-based therapies despite having higher baseline risk and therefore greater potential for absolute benefit.

The treatment gap has two components. The **prescription gap** means physicians do not prescribe appropriate medications, often from unjustified concerns about age, polypharmacy, or limited life expectancy. The **adherence gap** means patients are prescribed medications but do not take them consistently. Only 49% of elderly patients adhere to all three core therapies (statins, beta-blockers, ACE inhibitors)[30-1]. Medication non-adherence is directly linked to increased mortality, recurrent events, and hospitalizations[38]. Adherence is highest for antiplatelets (97%) and lowest for beta-blockers[30-2].

Both gaps are addressable. Asking the three questions at the end of this paper can close the prescription gap. Caregiver involvement, simplified regimens, and the monitoring strategies discussed below can close the adherence gap.

Lifestyle Interventions

Mediterranean Diet. The Lyon Diet Heart Study randomized 605 MI survivors to a Mediterranean diet versus a standard Western diet and followed them for a mean of 46 months[39]. The Mediterranean group experienced a 70% reduction in cardiovascular deaths and recurrent MI (14 events versus 44, P<0.0001)[39-1]. The mechanisms include favorable effects on lipid profile, reduced inflammation, improved endothelial function, and beneficial gut microbiome changes[39-2]. The Mediterranean diet is not a restriction program. It is an abundance program: olive oil, fish, vegetables, whole grains, nuts, and modest portions of poultry.

Mediterranean Diet at a Glance (Click to Expand) ›

Eat more: Extra virgin olive oil (daily),fish (2-3 times per week), vegetables and legumes, whole grains, nuts and seeds, fresh fruit

Eat moderately: Poultry, eggs, cheese, yogurt

Eat less: Red meat (1-2 times per month), processed meats, refined grains, added sugars, butter and cream

The key shift: Replace butter with olive oil, red meat with fish, refined grains with whole grains. This is not about deprivation—it is about substitution. The Lyon Diet Heart Study participants who made these changes experienced a 70% reduction in cardiovascular deaths[39-3].

Structured Exercise. AHA/ASA guidelines recommend 150 minutes per week of moderate-intensity aerobic activity plus resistance training two days per week for stroke survivors[15-2]. Resistance training at higher repetitions and reduced loads (10 to 15 repetitions per set) is safer and builds endurance and functional strength critical for activities of daily living[15-3]. For deconditioned elderly, the starting point is 5 to 10 minutes of walking three times per week, gradually increasing duration by 5 minutes weekly[15-4]. Every 1-MET increase in exercise capacity is associated with a 10 to 25% mortality reduction[18-2].

Smoking Cessation. Non-negotiable. Smoking is the single most modifiable risk factor for recurrent cardiovascular events[4-2]. Cardiovascular risk begins dropping within weeks of cessation[38-1]. Resources include nicotine replacement therapy, varenicline, behavioral counseling, and the national quit line (1-800-QUIT-NOW / 1-800-784-8669).

Weight Management. Modest weight loss of 5 to 10% of body weight improves lipid profiles, blood pressure, and insulin sensitivity. The focus should be on sustainable changes guided by a dietitian. For survivors who are overweight or obese, GLP-1 receptor agonists (such as semaglutide) have emerged as a significant addition to the secondary prevention toolkit. The SELECT trial (2023), enrolling over 17,000 patients with established cardiovascular disease, demonstrated that semaglutide reduced major adverse cardiovascular events by 20%[40]. Ask your cardiologist whether a GLP-1 receptor agonist may be appropriate as part of your treatment plan.

Stress, Sleep, and Mental Health. Depression is a modifiable risk factor that affects one in four stroke survivors[1-1]. Depressed patients are significantly less likely to adhere to medications, attend cardiac rehabilitation, or maintain lifestyle changes[30-3]. The cumulative risk of depression onset reaches 15.96% within 1.5 years after stroke, with 71% of cases emerging within the first three months[1-2] [41]. Screening for and treating depression improves both psychological well-being and cardiovascular outcomes.

Cardiac Rehabilitation

Cardiac rehabilitation is the most underused, most powerful intervention available to survivors. In the largest registry study of CR dose-response, completing 36 sessions was associated with a 47% lower risk of death compared to attending only 1 session[42]. The relationship is dosedependent: 12 sessions produce a 22 to 29% mortality reduction, 24 sessions produce 14 to 18%, and 36 sessions achieve the maximum 47 to 58% benefit[42-1]. Because this comes from observational registry data rather than a randomized trial, some of the benefit likely reflects the overall health characteristics of patients who complete the program—but even conservative estimates confirm that cardiac rehabilitation is among the most effective interventions available.



Figure 5: Every Session Counts. Mortality reduction increases with each block of cardiac rehabilitation sessions completed, reaching 47% at 36 sessions. Yet only 5.4% of elderly patients complete the full program. Data from Martin BJ et al., Circulation 2012 (registry data).

The paradox is devastating. Only 19 to 34% of eligible patients ever enroll[43]. Of those referred, only 34% actually attend. Completion rates in elderly patients are dismal: an estimated 5.4% complete the full 36-session program[43-1] [44].

Top Barriers and Solutions:

Barrier	Prevalence	Solution
Transportation (>30 min travel)	#1 barrier	Home-based cardiac rehabilitation (equally effective)
Lack of physician referral	40-80% never referred	Ask explicitly: "Can you refer me to cardiac rehab?"
Cost (≈$835 Medicare copays for 36 sessions)	Significant for fixed income	Verify Medicare coverage; explore financial assistance programs
Perceived lack of need ("I already walk")	Common	Cardiac rehab is medical therapy, not generic exercise
Depression and fear	27-30% of stroke survivors	CR includes psychological screening and support

Home-based cardiac rehabilitation deserves special emphasis. A 2023 Cochrane meta-analysis of multiple randomized controlled trials confirmed that home-based programs are equally effective as center-based

programs for improving mortality (risk ratio 1.19, 95% CI 0.65-2.16—meaning no meaningful difference in survival between the two approaches), exercise capacity, and quality of life[45]. MACE rates, exercise capacity gains, and health-related quality of life outcomes were equivalent between modalities[45-1]. A study of home-based CR in patients with a median age of 77 years (range 65-92) demonstrated improved exercise capacity even in this very elderly cohort with high comorbidity burden[45-2]. The AHA/ACC/AACVPR 2019 Scientific Statement supports home-based CR as "a reasonable option for selected clinically stable low- to moderate-risk patients"[43-2]. Delivery methods include telephone-based programs, mobile apps with wearable activity trackers, hybrid center-home models, and telemonitoring with remote coaching[44-1]. In elderly populations where transportation is the primary barrier, home-based CR may be the difference between 5% completion and meaningful participation.

5. Case Studies

Case Study 1: Post-MI Survivor, Standard Pathway

Walter, a 68-year-old retired postal worker, presented with an anterior STEMI, underwent single-vessel stenting, and was discharged with a sense of dread. His father had died of a heart attack at age 70, and Walter was convinced he was next. Baseline: LDL 142 mg/dL, CRP 4.8 mg/L.

Intervention. OMT was initiated: aspirin, ticagrelor, atorvastatin 80 mg, metoprolol, and lisinopril. Walter enrolled in center-based cardiac rehabilitation and completed 34 of 36 sessions. A dietitian guided his transition to a Mediterranean diet. He quit smoking after a 30-year history using varenicline and behavioral counseling.

Outcomes at 12 months. LDL fell from 142 to 52 mg/dL. CRP dropped from 4.8 to 1.2 mg/L. He lost 22 pounds. His 6-minute walk test improved from 320 to 485 meters, a 51% gain. He resumed weekend hiking with his grandchildren. No recurrent events.

Walter told his cardiologist: "I feel like I got my life back. I'm not just waiting to die." His emotional transformation mirrors the research: when survivors see concrete evidence of improvement, the fear-fatalism cycle gives way to empowerment and sustained adherence[2-1] [46].

Key Lesson: Standard optimal medical therapy, fully adhered to, with cardiac rehabilitation completion, produces dramatic improvements.

Case Study 2: Post-Stroke Survivor, Advanced Therapy

Eleanor, a 73-year-old retired attorney, suffered a left middle cerebral artery ischemic stroke with full neurological recovery. She had been taking atorvastatin 40 mg with suboptimal adherence before the stroke. Baseline LDL was 168 mg/dL.

Intervention. Her statin was increased to atorvastatin 80 mg, ezetimibe was added, and at 12-week follow-up her LDL was still 78 mg/dL, above the 70 mg/dL target. Inclisiran (a twice-yearly PCSK9 inhibitor injection)

was added. Because Eleanor lived in a rural area without convenient access to a cardiac rehabilitation center, she enrolled in a home-based CR program with telephone monitoring and a wearable activity tracker.

Outcomes at 18 months. LDL fell from 168 to 42 mg/dL on inclisiran[17-3]. CRP decreased from 3.4 to 1.1 mg/L[11-4]. Her 6-minute walk test improved from 380 to 465 meters[18-3]. She resumed playing tennis twice weekly. No recurrent events at 18-month follow-up.

Eleanor's case demonstrates three principles: advanced therapies provide incremental benefit when standard treatment is insufficient[20-2]; inclisiran's twice-yearly dosing solves the adherence challenge[17-4]; and home-based cardiac rehabilitation overcomes logistical barriers[45-3].

Key Lesson: When standard therapy is not enough, advanced options exist. Rural residence and transportation limitations are not reasons to forgo rehabilitation.



Figure 6: Before and After. Walter (post-MI, age 68) and Eleanor (post-stroke, age 73) both achieved dramatic improvements in LDL, CRP, and functional capacity with optimal medical therapy and cardiac rehabilitation. Neither experienced a recurrent event.

Themes Across Cases

Five patterns emerge from Walter's and Eleanor's experiences that generalize to most cardiovascular survivors. First, **emotional transformation follows evidence**: both shifted from fear and fatalism to empowerment once they could see their labs improving and their functional capacity returning. Second, **laboratory markers reinforce adherence**: the quarterly proof that LDL and CRP are falling creates a positive feedback loop that sustains long-term medication compliance. Third, **medication and lifestyle are synergistic**: neither Walter's diet changes nor Eleanor's exercise program alone would have produced the same results without concurrent optimal medical therapy—and vice versa. Fourth, **cardiac rehabilitation completion is the multiplier**: Walter's 34 sessions and Eleanor's home-based program were the common thread that amplified every other intervention. Fifth, **age was a reason to treat, not a reason to wait**: at 68 and 73 respectively, both patients had high enough baseline risk that every intervention delivered a larger absolute benefit than it would have in a younger patient.

6. Frequently Asked Questions and Common Objections

"Am I too old for aggressive treatment to matter?"

No. The Singapore National Registry demonstrated that patients aged 90 and older benefit from every class of guideline-directed medical therapy[28-3]. Because elderly patients have higher baseline cardiovascular risk, the same relative risk reduction translates to a larger absolute benefit. A 46% relative mortality reduction means your risk drops by almost half. If 100 elderly survivors face a 5% chance of dying this year without treatment, optimal therapy reduces that to 2.7%—saving roughly 2 to 3 lives per 100 people treated each year[25-4]. Your age is a reason to treat aggressively, not to withhold therapy.

"How do I know if treatment is actually working?"

Laboratory proof: LDL cholesterol drops within 4 to 6 weeks on statins and reaches maximum effect by 12 weeks on PCSK9 inhibitors[17-5]. CRP reduction is visible by 8 to 12 weeks. **Functional proof:** walking further, carrying groceries without breathlessness, resuming activities you had stopped. Cardiac rehabilitation produces measurable gains in 6-minute walk distance averaging 95 meters[18-4]. **Clinical proof:** every year without a recurrent event is objective evidence your treatment is working.

"I'm already on a statin. Isn't that enough?"

Statins are essential but often insufficient alone. Optimal medical therapy consists of five components: antiplatelet therapy, high-intensity statin, beta-blocker (post-MI), ACE inhibitor or ARB, and advanced lipid-lowering when needed. The GLAGOV trial showed that PCSK9 inhibitors plus statins achieved 2.9% plaque regression compared to 0.4% with statins alone[13-4]. Ask your cardiologist: "Am I on all five components of optimal medical therapy? If not, why not?"

"What if I can't tolerate statins?"

The SAMSON trial found that 90% of symptoms attributed to statins were nocebo effects, occurring equally on placebo[47]. Patients could not subjectively distinguish statin from placebo. True pharmacological statin myopathy occurs in fewer than 1 to 5% of patients. For those with genuine intolerance, alternatives include lower-dose statin plus ezetimibe, bempedoic acid, and PCSK9 inhibitors. Statin intolerance is never a reason to abandon lipid lowering.

The SAMSON Trial: What Statin Side Effects Really Are (Click to Expand)

In a rigorous crossover trial, 60 patients cycled through statin, placebo, and no-tablet phases in random order. They could not tell the difference:

90% of reported side effects occurred equally whether they were taking the statin or the placebo[47-1]. This means most statin "intolerance" is a nocebo effect—symptoms caused by the expectation of side effects, not by the medication itself.

True pharmacological statin myopathy occurs in fewer than 1 to 5% of patients. If you stopped your statin due to side effects, discuss a rechallenge with your physician. The 46% mortality benefit of optimal medical therapy may be recoverable. Alternatives include lower-dose statin combined with ezetimibe, bempedoic acid, or PCSK9 inhibitors—all of which achieve meaningful LDL reduction without the same muscle pathway.

"Isn't it too late? The damage is already done."

ASTEROID demonstrated 6.8% plaque volume regression. GLAGOV demonstrated 2.9% regression with combination therapy. The Iatan metaanalysis confirmed that every 1% plaque regression produces a 19 to 25% reduction in future events[22-1]. Fibrous cap thickness nearly tripled in 12 months with PCSK9 inhibitor therapy[12-3]. Optimal medical therapy reduces one-year mortality by 46%[16-6]. Your arteries can heal. The science is unambiguous.

"What about cardiac rehab? I already exercise."

Cardiac rehabilitation is not generic exercise. It is supervised, personalized medical therapy delivered through structured movement, nutritional counseling, medication management, and psychological support. The 47% mortality association for completers—while partly reflecting the health characteristics of patients who finish the program—places it among the most impactful interventions available[42-2]. If transportation is a barrier, home-based programs are equally effective[45-4].

"How long do I need to stay on these medications?"

Lifelong, in most cases. Atherosclerosis is a chronic disease requiring chronic management. Benefits persist as long as treatment continues[19-3]. Stopping statin therapy allows LDL cholesterol to rise within weeks, inflammatory markers to return to baseline, and plaques to begin destabilizing[11-5]. Ten-year follow-up data show that stroke recurrence protection is fully maintained with continuous statin therapy[19-4]. The exception is dual antiplatelet therapy, which is typically limited to 6 to 12 months post-ACS before transitioning to aspirin alone.

"What if I have other health problems?"

Comorbidities require adjustments, not treatment abandonment. Patients with diabetes still benefit from statins[26-5]. Chronic kidney disease may require dose adjustments but does not eliminate the benefit of lipid-lowering therapy. Polypharmacy concerns are valid but should focus on prioritizing the highest-impact medications: the five components of OMT have the strongest mortality data[16-7]. Even frail elderly patients benefit from guideline-directed therapy, with the Singapore nonagenarian study confirming survival benefits at the extremes of age and health status[28-4]. The principle is personalization: work with your care team to optimize therapy for your specific situation.

7. Summary and Next Steps



Figure 7: The Evidence in Numbers. 46% mortality reduction with optimal medical therapy. 70% risk reduction with Mediterranean diet in secondary prevention. 47% mortality reduction with 36 sessions of cardiac rehabilitation.

Five Things to Remember

1. **Plaque regression is real.** Imaging trials prove plaques shrink and stabilize. Outcomes trials confirm this saves lives. Every 1% plaque regression reduces future events by 19 to 25%.
2. **Age is not a barrier.** Benefits persist to age 90 and beyond. Elderly patients benefit equally or more because their higher baseline risk translates to greater absolute benefit.
3. **You have agency.** Optimal medical therapy, lifestyle changes, and cardiac rehabilitation give you remarkable control over your future. The 46% mortality reduction, the 61% stroke reduction, the 47% cardiac rehab benefit: these are tools in your hands.
4. **The proof is accessible.** You will see it in your labs (LDL and CRP falling), in how you feel (walking further, more energy), and in time (every year without a recurrent event).
5. **It is not too late.** Your arteries can heal. The science is unambiguous.

Your Action Plan: Within 30 Days

Action 1□ Schedule a cardiology appointment. Ask three questions:

1. "Am I on all five components of optimal medical therapy?"
2. "Is my LDL at goal (below 70 mg/dL, ideally below 55)? If not, can we intensify therapy?"
3. "Can you refer me to cardiac rehabilitation?"

Action 2□ Enroll in cardiac rehabilitation. Request a referral at your cardiology appointment. Choose center-based or home-based depending on your logistics. Commit to completing the full program.

Action 3□ Begin one lifestyle change this week. Mediterranean diet: start with one meal change per week. Exercise: 10-minute walks three times per week. Smoking cessation: call 1-800-QUIT-NOW today.

Action 4□ Create an implementation intention. Implementation intentions are "if-then" plans that bridge the gap between wanting to do something and actually doing it[48]. Format: "If [situation], then I will [behavior]." Example: "If it is Monday morning after breakfast, then I will call to schedule my cardiology appointment." Meta-analyses show that implementation intentions approximately double the probability of health behavior follow-through[48-1] [46-1]. Write it down. Share it with your caregiver.

For Caregivers

If you are reading this paper because someone you love had a heart attack or stroke, this section is for you. For patients aged 65 to 85, the caregiver—often a spouse or adult child—is frequently the person who drives the behavior changes that determine outcomes. Caregiver involvement reduces medication non-adherence by 40 to 50%[49]. You are not a bystander. You are a co-engineer of recovery.

Attend appointments together. Be the second set of ears. Bring a written list of questions. Take notes on what the physician says—post-stroke cognitive impairment affects up to 60% of survivors[3-1], and even without cognitive changes, medical appointments are overwhelming after a cardiovascular event. Ask the three questions in the Action Plan above if your loved one doesn't.

Be the medication partner. Help organize medications in a weekly pillbox. Track refill dates. Know what each medication does and why it matters —the five pillars of optimal medical therapy described in Section 4 are your roadmap. Medication adherence drops sharply when patients manage complex regimens alone[38-2].

Join lifestyle changes. Cook Mediterranean meals together rather than preparing separate "healthy" and "normal" meals. Walk together after dinner. These shared activities reinforce adherence far more effectively than reminding from a distance. If your loved one is enrolled in home-based cardiac rehabilitation, participate in the exercise sessions alongside them when possible.

Monitor for depression. One in four stroke survivors develops depression, with 71% of cases emerging in the first three months[1-3]. Depression undermines every other intervention: depressed patients are less likely to

take medications, attend rehabilitation, or maintain dietary changes[30-4]. Watch for withdrawal, loss of interest, sleep changes, and persistent hopelessness, and bring these observations to the care team.

Provide accountability with compassion. Recovery is not linear. There will be setbacks, missed doses, skipped walks, and emotionally difficult days. Your role is not to police but to partner: celebrate every small win, normalize imperfection, and keep showing up. Even weekly caregiver contact is independently protective[49-1] [50].

Caregiver Quick Reference Checklist (Click to Expand)

At the cardiology appointment:

- Attend together; bring a written list of questions
- Ask the three questions if your loved one doesn't: (1) All five OMT components? (2) LDL at goal? (3) Cardiac rehab referral?
- Take notes on what the physician says

Medication management:

- Set up a weekly pillbox; track refill dates
- Learn the five pillars of OMT—know what each medication does and why

Lifestyle partnership:

- Cook and eat Mediterranean meals together
- Walk together after dinner (or join home-based CR sessions)

Monitoring:

- Watch for depression signs: withdrawal, loss of interest, sleep changes, persistent hopelessness
- Report concerns to the care team early—71% of post-stroke depression emerges in the first three months

Every day:

- Celebrate every small win
- Keep showing up

Remember: your arteries can heal. It is not too late.

Conflicts of Interest: None declared.
Funding: No external funding was received for this white paper.
Disclaimer: This document is intended for educational purposes and does not constitute individualized medical advice. Readers should consult qualified healthcare providers for personal medical decisions.

8. Glossary of Terms and Abbreviations

ACE Inhibitor (Angiotensin-Converting Enzyme Inhibitor): Medication that lowers blood pressure and protects the heart by blocking the enzyme that produces angiotensin II, a substance that narrows blood vessels. Examples: lisinopril, ramipril, enalapril.

ACS (Acute Coronary Syndrome): Umbrella term for sudden conditions caused by reduced blood flow to the heart, including heart attacks (STEMI, NSTEMI) and unstable angina. The Canadian ACS registries are a key evidence source in this paper.

ARB (Angiotensin Receptor Blocker): Alternative to ACE inhibitors for blood pressure control and cardiac protection. Used when ACE inhibitors cause cough or other side effects. Examples: losartan, valsartan.

Atherosclerosis: The process by which cholesterol, immune cells, and other materials accumulate in artery walls, forming plaques that can narrow arteries and rupture to cause heart attacks and strokes. The central disease process addressed throughout this paper.

CRP (C□Reactive Protein): A blood marker of inflammation produced by the liver. When measured with a high-sensitivity assay (hs-CRP), it reflects low-grade vascular inflammation relevant to cardiovascular disease. Target: below 2 mg/L.

DAPT (Dual Antiplatelet Therapy): The combination of aspirin plus a second antiplatelet agent (clopidogrel, ticagrelor, or prasugrel), used for 6 to 12 months after an acute coronary syndrome to prevent stent thrombosis and recurrent events.

Fibrous Cap: The layer of smooth muscle cells and collagen that covers an atherosclerotic plaque. A thick cap protects against plaque rupture. Cap thickening is a primary goal of aggressive lipid-lowering therapy.

GDMT (Guideline-Directed Medical Therapy): The combination of medications recommended by ACC/AHA guidelines for cardiovascular disease management. In the nonagenarian study, GDMT classes include beta-blockers, antiplatelets, statins, and ACE inhibitors/ARBs.

IVUS (Intravascular Ultrasound): An imaging technique that uses a tiny ultrasound probe inserted into a coronary artery to measure plaque volume from inside the vessel. The gold standard for plaque regression measurement in research trials (ASTEROID, GLAGOV).

LDL□C (Low-Density Lipoprotein Cholesterol): The "bad cholesterol." Measures the mass of cholesterol within LDL particles. Target in secondary prevention: below 70 mg/dL, ideally below 55 mg/dL.

MACE (Major Adverse Cardiovascular Events): A composite endpoint in clinical trials typically including cardiovascular death, myocardial infarction, and stroke. The Iatan meta-regression linked plaque regression to MACE reduction.

NNT (Number Needed to Treat): The number of patients who must receive a treatment for one additional patient to benefit. Lower NNT means more effective treatment. Statins in secondary prevention: NNT 30-37 over five years to prevent one death.

OMT (Optimal Medical Therapy): The five-component medication regimen (antiplatelet, statin, beta-blocker, ACE-i/ARB, advanced lipid-lowering when needed) proven to reduce mortality by 46% in acute coronary syndrome survivors.

PAV (Percent Atheroma Volume): A measure of plaque burden expressed as the percentage of vessel area occupied by plaque, used in IVUS-based regression trials.

PCSK9 Inhibitor: A class of medications (evolocumab, alirocumab, inclisiran) that dramatically lower LDL cholesterol by 50-65% by preventing the degradation of LDL receptors on liver cells. Used when statins and ezetimibe are insufficient.

TAV (Total Atheroma Volume): The absolute volume of plaque measured by IVUS, used alongside PAV to quantify plaque regression in imaging trials.

Kayur V. Patel, MD
KayurVPatel@MyPrivate.MD

9. References

1. Liu L, Xu M, Marshall IJ, et al. Prevalence and natural history of depression after stroke: a systematic review and meta-analysis of observational studies. PLoS Med. 2023;20(3):e1004200. PMID: 36976794. https://pubmed.ncbi.nlm.nih.gov/36976794/ DOI: https://doi.org/10.1371/journal.pmed.1004200
2. Tannenbaum MB, et al. Appealing to fear: a meta-analysis of fear appeal effectiveness and theories. Psychol Bull. 2015;141(6):1178-1204. PMID: 26501228. https://pubmed.ncbi.nlm.nih.gov/26501228/ DOI: https://doi.org/10.1037/a0039729
3. El Husseini N, et al. Post-stroke cognitive impairment: clinical implications and effects on functional outcome. Stroke. 2023;54(6):1630-1641. PMID: 37125534. https://pubmed.ncbi.nlm.nih.gov/37125534/ DOI: https://doi.org/10.1161/STR.0000000000000430
4. Martin SS, et al. 2024 Heart Disease and Stroke Statistics: a report of US and global data from the AHA. Circulation. 2024;149(8):e347-e913. PMID: 38264914. https://pubmed.ncbi.nlm.nih.gov/38264914/ DOI: https://doi.org/10.1161/CIR.0000000000001209
5. Imoisili OE, Chung A, Tong X, Hayes DK, Loustalot F. Prevalence of stroke - Behavioral Risk Factor Surveillance System, United States, 2011-2022. MMWR. 2024;73(20):449-455. PMID: 38781110. https://pubmed.ncbi.nlm.nih.gov/38781110/ DOI: https://doi.org/10.15585/mmwr.mm7320a1
6. Aked J, Delavaran H, Lindgren AG. Survival, causes of death and recurrence up to 3 years after stroke: a population-based study. Eur J Neurol. 2021;28(12):40604068. PMID: 34327786. https://pubmed.ncbi.nlm.nih.gov/34327786/ DOI: https://doi.org/10.1111/ene.15041
7. Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391-399. PMID: 30697776. https://pubmed.ncbi.nlm.nih.gov/30697776/ DOI: https://doi.org/10.1002/clc.23160

8. Nissen SE, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial (REVERSAL). JAMA. 2004;291(9):1071-1080. PMID: 14996776. https://pubmed.ncbi.nlm.nih.gov/14996776/ DOI: https://doi.org/10.1001/jama.291.9.1071
9. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;14(2):177-192. PMID: 8305407. https://pubmed.ncbi.nlm.nih.gov/8305407/ DOI: https://doi.org/10.1161/01.ATV.14.2.177
10. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. PMID: 16533939. https://pubmed.ncbi.nlm.nih.gov/16533939/ DOI: https://doi.org/10.1001/jama.295.13.jpc60002
11. Ridker PM, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-28. PMID: 15635109. https://pubmed.ncbi.nlm.nih.gov/15635109/ DOI: https://doi.org/10.1056/NEJMoa042378
12. Raber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771-1781. PMID: 35368058. https://pubmed.ncbi.nlm.nih.gov/35368058/ DOI: https://doi.org/10.1001/jama.2022.5218
13. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373-2384. PMID: 27846344. https://pubmed.ncbi.nlm.nih.gov/27846344/ DOI: https://doi.org/10.1001/jama.2016.16951
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29-38. PMID: 15635110. https://pubmed.ncbi.nlm.nih.gov/15635110/ DOI: https://doi.org/10.1056/NEJMoa042000
15. Billinger SA, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the AHA/ASA. Stroke. 2014;45(8):2532-2553. PMID: 24846875. https://pubmed.ncbi.nlm.nih.gov/24846875/ DOI: https://doi.org/10.1161/STR.0000000000000022
16. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J. 2007;154(6):1108-1115. PMID: 18035083. https://pubmed.ncbi.nlm.nih.gov/18035083/ DOI: https://doi.org/10.1016/j.ahj.2007.07.040
17. Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: a state-of-the-art review. Pharmacotherapy. 2025;45(1):54-65. PMID: 39679827. https://pubmed.ncbi.nlm.nih.gov/39679827/ DOI: https://doi.org/10.1002/phar.4635
18. Wicks JR, Turner GT, Leslie SL, Jayasinghe R. Changes observed in the 6-minute walk test in response to exercise-based cardiac rehabilitation. Exerc Med. 2022;6:2. DOI: https://doi.org/10.26644/em.2022.002
19. Cheng E, et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology. 2009;72(22):1932-1938. PMID: 19470963. https://pubmed.ncbi.nlm.nih.gov/19470963/ DOI: https://doi.org/10.1212/WNL.0b013e3181a711cb
20. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. PMID: 28304224. https://pubmed.ncbi.nlm.nih.gov/28304224/ DOI: https://doi.org/10.1056/NEJMoa1615664

21. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. PMID: 30403574. https://pubmed.ncbi.nlm.nih.gov/30403574/ DOI: https://doi.org/10.1056/NEJMoa1801174

22. Iatan I, et al. Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated meta-regression analysis. JAMA Cardiol. 2023;8(10):937-945. PMID: 37647074. https://pubmed.ncbi.nlm.nih.gov/37647074/ DOI: https://doi.org/10.1001/jamacardio.2023.2731

23. Mechtouff L, Haesebaert J, Viprey M, et al. Secondary prevention three and six years after stroke using the French National Insurance Healthcare System database. Eur Neurol. 2018;79(5-6):272-280. PMID: 29758555. https://pubmed.ncbi.nlm.nih.gov/29758555/ DOI: https://doi.org/10.1159/000488450

24. Zhang P, et al. PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis. J Neurol Neurosurg Psychiatry. 2024;95(5):421-427. PMID: 38212060. https://pubmed.ncbi.nlm.nih.gov/38212060/ DOI: https://doi.org/10.1136/jnnp-2023-332392

25. LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435. PMID: 15755765. https://pubmed.ncbi.nlm.nih.gov/15755765/ DOI: https://doi.org/10.1056/NEJMoa050461

26. Bao A, Karalis DG. Statin therapy for primary and secondary prevention in older adults. Curr Atheroscler Rep. 2024;27(1):11. PMID: 39585440.

https://pubmed.ncbi.nlm.nih.gov/39585440/ DOI: https://doi.org/10.1007/s11883-024-01257-9

27. Ng KH, Hart RG, Eikelboom JW. Anticoagulation in patients aged ≥75 years with atrial fibrillation: role of novel oral anticoagulants. Cardiol Ther. 2013;2(2):135-149. PMID: 25135392. https://pubmed.ncbi.nlm.nih.gov/25135392/ DOI: https://doi.org/10.1007/s40119-013-0019-y

28. Ong TH, et al. Guideline-directed medical therapy in nonagenarians and centenarians (≥90 years old) after first-onset myocardial infarction: a national registry study. Can J Cardiol. 2025. PMID: 39894212. https://pubmed.ncbi.nlm.nih.gov/39894212/ DOI: https://doi.org/10.1016/j.cjca.2025.01.031

29. Gurwitz JH, Goldberg RJ. Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals. Arch Intern Med. 2011;171(6):557-558. PMID: 21444845. https://pubmed.ncbi.nlm.nih.gov/21444845/ DOI: https://doi.org/10.1001/archinternmed.2011.33

30. Choudhry NK, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17(12):1189-1196. PMID: 18956426. https://pubmed.ncbi.nlm.nih.gov/18956426/ DOI: https://doi.org/10.1002/pds.1671

31. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9-19. PMID: 31738483. https://pubmed.ncbi.nlm.nih.gov/31738483/ DOI: https://doi.org/10.1056/NEJMoa1910355

32. Hong KS, Bang OY, Park JH, et al. Moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target low-density lipoprotein cholesterol goal achievement in patients with recent ischemic stroke: a randomized controlled trial. J Stroke. 2023;25(2):242-250. PMID: 37032475. https://pubmed.ncbi.nlm.nih.gov/37032475/ DOI: https://doi.org/10.5853/jos.2022.02957

33. Ahmed S, et al. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia. BMC Cardiovasc Disord. 2024;24:645. PMID: 39521985. https://pubmed.ncbi.nlm.nih.gov/39521985/ DOI: https://doi.org/10.1186/s12872-024-04321-z

34. Kazi DS, Lu CY, Lin GA, et al. Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans. JAMA Cardiol. 2017;2(10):1164-1166. PMID: 28903137. https://pubmed.ncbi.nlm.nih.gov/28903137/ DOI: https://doi.org/10.1001/jamacardio.2017.3051

35. Sosnowska B, Toth PP, Razavi AC, et al. 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings. Arch Med Sci. 2025;21(2):355-373. PMID: 40395905. https://pubmed.ncbi.nlm.nih.gov/40395905/ DOI: https://doi.org/10.5114/aoms/202213

36. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. PMID: 31733140. https://pubmed.ncbi.nlm.nih.gov/31733140/ DOI: https://doi.org/10.1056/NEJMoa1912388

37. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. PMID: 32865380. https://pubmed.ncbi.nlm.nih.gov/32865380/ DOI: https://doi.org/10.1056/NEJMoa2021372

38. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035. PMID: 19528344. https://pubmed.ncbi.nlm.nih.gov/19528344/ DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.768986

39. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785. PMID: 9989963. https://pubmed.ncbi.nlm.nih.gov/9989963/ DOI: https://doi.org/10.1161/01.cir.99.6.779

40. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/ DOI: https://doi.org/10.1056/NEJMoa2307563

41. Mayman N, Stein LK, Erdman J, et al. Risk and predictors of depression following acute ischemic stroke in the elderly. Neurology. 2021;96(17):e2184-e2191. PMID: 33722998. https://pubmed.ncbi.nlm.nih.gov/33722998/ DOI: https://doi.org/10.1212/WNL.0000000000011828

42. Martin BJ, Hauer T, Arena R, et al. Cardiac rehabilitation attendance and outcomes in coronary artery disease patients. Circulation. 2012;126(6):677-687. PMID: 22777176. https://pubmed.ncbi.nlm.nih.gov/22777176/ DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.066738

43. Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation. 2011;124(25):2951-2960. PMID: 22082676. https://pubmed.ncbi.nlm.nih.gov/22082676/ DOI: https://doi.org/10.1161/CIR.0b013e31823b21e2

44. Chindhy S, Taub PR, Lavie CJ, Shen J. Current challenges in cardiac rehabilitation: strategies to overcome social factors and attendance barriers. Expert Rev Cardiovasc Ther. 2020;18(11):777-789. PMID: 32885702. https://pubmed.ncbi.nlm.nih.gov/32885702/ DOI: https://doi.org/10.1080/14779072.2020.1816464

45. McDonough S, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023;10:CD007130. PMID: 37888805.

https://pubmed.ncbi.nlm.nih.gov/37888805/ DOI: https://doi.org/10.1002/14651858.CD007130.pub5

46. Seligman HK, et al. Facilitating behavior change with low-literacy patient education materials. Am J Health Behav. 2007;31(Suppl 1):S69-S78. PMID: 17931139. https://pubmed.ncbi.nlm.nih.gov/17931139/ DOI: https://doi.org/10.5555/ajhb.2007.31.supp.S69

47. Howard JP, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210-1222. PMID: 34531021. https://pubmed.ncbi.nlm.nih.gov/34531021/ DOI: https://doi.org/10.1016/j.jacc.2021.07.022

48. Xu L, Pinxten W, Vandereyt F, et al. Motivational communication skills to improve motivation and adherence in cardiovascular disease prevention: a narrative review. Clin Cardiol. 2023;46(12):1474-1480. PMID: 37675783. https://pubmed.ncbi.nlm.nih.gov/37675783/ DOI: https://doi.org/10.1002/clc.24128

49. Creasy KR, et al. Medication adherence is associated with having a caregiver among cardiac patients. Ann Behav Med. 2013;46(2):237-242. PMID: 23536121. https://pubmed.ncbi.nlm.nih.gov/23536121/ DOI: https://doi.org/10.1007/s12160-013-9492-8

50. Foebel AD, Hirdes JP, Heckman GA. Caregiver status affects medication adherence among older home care clients with heart failure. Aging Clin Exp Res.
2012;24(6):718-727. PMID: 22732397. https://pubmed.ncbi.nlm.nih.gov/22732397/ DOI:
https://doi.org/10.3275/8475